← Back to list
Genetic Cancer Susceptibility Panels Using Next Generation Sequencing
Effective date
Not stated in the notice
Identified
Jun 20, 2026
Summary
General genetic cancer susceptibility panel testing is considered investigational. Limited panels that include only the gene variants for which a member qualifies may be considered medically necessary when the coverage criteria of other related policies are met. Individual components of a panel may still be medically necessary, and the Genetic Testing medical policy applies to those components.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.
Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.
What to do
Action · 5 steps
01Billing team: General genetic cancer susceptibility panel testing is considered investigational under this policy, so do not bill a general panel as medically necessary.
02Before billing a limited panel, confirm the member meets the coverage criteria of the related policies, and include only the gene variants for which that member qualifies.
03Individual panel components that may be medically necessary are covered under the Genetic Testing medical policy.
04For breast and ovarian cancer syndrome testing, refer to the Germline Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers (BRCA1, BRCA2, PALB2) medical policy.
05BCBSMS makes no payment for services not documented to be Medically Necessary.
Codes mentioned
8112081121814328143781445814508145581457814588145981462814638146481479
Original notice
Genetic Cancer Susceptibility Panels Using Next Generation Sequencing
bcbsms.com · Always check the source before changing claims.
Related changes
See all Blue Cross & Blue Shield of Mississippi changes →Germline Genetic Testing for Pancreatic Cancer Susceptibility Genes (ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, and TP53)MediumNo effective date · Medical PolicyGermline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Prostate Cancer (BRCA1/2, Homologous Recombination Repair Gene Alterations, NTRK Gene Fusion)MediumNo effective date · Medical PolicyGenetic Testing for FLT3, NPM1, CEBPA, IDH1, and IDH2 Variants in Cytogenetically Normal Acute Myeloid LeukemiaMediumNo effective date · Medical PolicyGermline Genetic Testing for Hereditary Diffuse Gastric Cancer (CDH1, CTNNA1)MediumEffective Oct 1, 2026 · Medical PolicyBrowse every Blue Cross & Blue Shield of Mississippi change in the policy list